other material
confidence high
sentiment neutral
materiality 0.60
Aclaris Therapeutics enters $200M ATM equity facility, terminates prior $150M ATM
Aclaris Therapeutics, Inc.
- New Sales Agreement with SVB Securities and Cantor Fitzgerald for up to $200M in common stock at-the-market.
- Prior $150M ATM terminated; $72.7M net proceeds raised from 4.8M shares under prior agreement.
- Commission of 3% of gross proceeds on sales under new agreement.
- Company not obligated to sell any shares; offering at its sole discretion.